$PTX - Prescient Therapeutics - Strong news on cancer treatment
Popped up on my volume alerts and bought on the pullback. Went as high as 10 cents on some pretty strong news!
ANNOUNCEMENT:
================================
Melbourne, Australia (10 December 2018): Clinical-stage oncology company Prescient Therapeutics Limited (ASX: PTX; Prescient) is pleased to announce interim durability data on the PTX-200 study in HER2 negative, locally advanced breast cancer.
Follow-up studies have determined that none of the five responders in the Phase 2 component of the trial have had disease progression to date.
Progression Free Survival (PFS), which is the time from the start of treatment until disease recurrence or progression, ranges from 22.8 months to 30.4 months so far, with an average of 27 months. All patients remain progression free to date.
Overall survival (OS), which is the time from start of treatment until patient death, exhibits the same average duration of 27 months as none of the patients have passed away.
To date, not only did patients with pathological complete responses (pCR) remain free of disease progression, but interestingly all patients that had partial responses (PRs) also remain free of disease progression after over two years
ABOUT:
================================
Prescient Therapeutics Limited is a clinical-stage oncology company. The Company is engaged in the preparation for and conduct of clinical trials relating to the companies drugs; business development associated with the promotion of its technologies and products, and business development associated with developing collaborative, partnership relationships and corporate transactions. The Company is engaged in developing compounds to treat a range of solid and hematological cancers. It is pursuing the clinical and commercial development of two cancer compounds: PTX-200 and PTX-100. PTX-200 inhibits a tumor survival pathway, which plays a key role in the development of cancers. PTX-100 is a drug that kills cancer cells by blocking geranylgeranyl ransferase-1 (GGT-1). PTX-200 is in Phase Ib/IIa trials in breast and ovarian cancers, and focuses on an accruing patient for leukemia trials. PTX-100 is in Phase I of its clinical trials for breast cancer and multiple Myeloma.
ANNOUNCEMENT:
================================
Melbourne, Australia (10 December 2018): Clinical-stage oncology company Prescient Therapeutics Limited (ASX: PTX; Prescient) is pleased to announce interim durability data on the PTX-200 study in HER2 negative, locally advanced breast cancer.
Follow-up studies have determined that none of the five responders in the Phase 2 component of the trial have had disease progression to date.
Progression Free Survival (PFS), which is the time from the start of treatment until disease recurrence or progression, ranges from 22.8 months to 30.4 months so far, with an average of 27 months. All patients remain progression free to date.
Overall survival (OS), which is the time from start of treatment until patient death, exhibits the same average duration of 27 months as none of the patients have passed away.
To date, not only did patients with pathological complete responses (pCR) remain free of disease progression, but interestingly all patients that had partial responses (PRs) also remain free of disease progression after over two years
ABOUT:
================================
Prescient Therapeutics Limited is a clinical-stage oncology company. The Company is engaged in the preparation for and conduct of clinical trials relating to the companies drugs; business development associated with the promotion of its technologies and products, and business development associated with developing collaborative, partnership relationships and corporate transactions. The Company is engaged in developing compounds to treat a range of solid and hematological cancers. It is pursuing the clinical and commercial development of two cancer compounds: PTX-200 and PTX-100. PTX-200 inhibits a tumor survival pathway, which plays a key role in the development of cancers. PTX-100 is a drug that kills cancer cells by blocking geranylgeranyl ransferase-1 (GGT-1). PTX-200 is in Phase Ib/IIa trials in breast and ovarian cancers, and focuses on an accruing patient for leukemia trials. PTX-100 is in Phase I of its clinical trials for breast cancer and multiple Myeloma.
Comment:
Didn't rally as hoped but My stop loss is in at .063 to allow it to ride for a little longer. I suspect it will be quite spiky on news so happy to wait a while.
NOT TRADING ADVICE. ALWAYS DO YOUR OWN RESEARCH.
FIND TRAILING STOPS: SuperTrail.io
FIND COINS BREAKING OUT: CoinRaces.cc
MY YOUTUBE TRADINGVIEW TIPS AND TRICKS: bit.ly/3kRW08o
MEXC FOR CRYPTO: bit.ly/47QCeNR
FIND TRAILING STOPS: SuperTrail.io
FIND COINS BREAKING OUT: CoinRaces.cc
MY YOUTUBE TRADINGVIEW TIPS AND TRICKS: bit.ly/3kRW08o
MEXC FOR CRYPTO: bit.ly/47QCeNR